Title:
掻痒抑制剤
Document Type and Number:
Japanese Patent JP5201795
Kind Code:
B2
Inventors:
Tetsuo Koike
Mayumi Hamaura
Mayumi Hamaura
Application Number:
JP2006004630A
Publication Date:
June 05, 2013
Filing Date:
January 12, 2006
Export Citation:
Assignee:
Rohto Pharmaceutical Co., Ltd.
International Classes:
A61K31/70; A61K31/045; A61K31/125; A61K31/198; A61K31/352; A61K31/4402; A61K47/02; A61K47/14; A61K47/34; A61P27/02
Domestic Patent References:
| JP2002332249A | ||||
| JP2004359629A | ||||
| JP2003081872A | ||||
| JP5178753A | ||||
| JP2002332248A | ||||
| JP11504948A |
Foreign References:
| WO2004052378A1 |
Other References:
Dry Eye,Practical Optometry ,2001年,Vol.12 No.1,pp.17-20
Yoshida T et al. ,Alginic acid oligosaccharide suppresses Th2 development and IgE production by inducing IL-12 production.,Int Arch Allergy Immunol.,2004年 3月,Vol.133 no.3,pp.239-247
Butrus S et al.,Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.,Clin Ther.,2000年12月,Vol.22 no.12,pp.1462-1472
Bielory L.,Ocular allergy treatments,Clinical Reviews in Allergy and Immunology,2001年,Vol.20,pp.201-213
Yoshida T et al. ,Alginic acid oligosaccharide suppresses Th2 development and IgE production by inducing IL-12 production.,Int Arch Allergy Immunol.,2004年 3月,Vol.133 no.3,pp.239-247
Butrus S et al.,Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.,Clin Ther.,2000年12月,Vol.22 no.12,pp.1462-1472
Bielory L.,Ocular allergy treatments,Clinical Reviews in Allergy and Immunology,2001年,Vol.20,pp.201-213
Attorney, Agent or Firm:
Yoshiki Hasegawa
Yoshinori Shimizu
Toshiaki Sakanishi
Yoshinori Shimizu
Toshiaki Sakanishi